ClinicalTrials.gg
Active, not recruitingNCT05462860Updated Aug 13, 2026

Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds

An interventional study of Suprathel® in Wound of Skin and Burns, sponsored by The Metis Foundation. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by The Metis Foundation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 336 studies in Burns with a site in United States — 40 open to participants now, 51 under way, 5 of them phase 3. Burns · United States.

Planned enrollment
149th of 272
21 · median 26
Started
2024
with 10 others
No phase
152 of 336
14 open now
Primary completion
2026-12
later than 18 of 50 live
Registered
282nd of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 149th largest by planned enrollment of the 272 interventional ones that give a count, is one of 11 that started in 2024, is one of 152 with no phase, reaches primary completion later than 18 of the 50 other live ones, and was the 282nd registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of reduction of pain, infection, provider workload, scar development and costs compared to SoC.

Read the detailed description

We are advocating the study of Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany), a synthetic wound dressing made of polymers of D-,L- lactate, and ε caprolactone, in the early coverage of burns for use in Large Scale Combat Operations (LSCOs) as compared to standard of care. The rationale for studying Suprathel® is its favorable physical characteristics as a portable treatment, ease of application by personnel without formal medical training, proven efficacy in improving outcomes after partial-thickness burn injury to include better pain control, preliminary evidence in decreasing burn wound conversion, and the lack of adverse consequences in covering indeterminant depth or full thickness burns.

03

Conditions studied

  • Wound of Skin
  • Burns

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female ≥18 years and ≤75 years
  • Acute partial thickness burns by friction, contact, scalding from hot liquids and flame
  • TBSA total ≥2 %; burn treatment region of interest: all areas with partial-thickness burns excluding face, neck, scalp, and feet
  • TBSA 3rd ≤5 % (not to be included as burn treatment region of interest)
  • Subject is able and willing to sign or via legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • Study Wound due to electrical, radioactive, or frostbite-related injury
  • Infection of wounds in the study area at admission per Investigator or treating physician discretion
  • Pregnancy/lactation
  • Subjects who are unable to follow the protocol or who are likely to be non-compliant
  • Participation in an active treatment arm of a burn wound related interventional study within 90 days of Screening Visit or during the study
  • Prisoners
  • less than 6 months
  • Subjects who are receiving , chronic anticoagulants, or immune suppressive treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Suprathel® dressing

    The Suprathel® dressing will be applied to the wound site after standard of care cleaning and debridement. The dressing will be maintained according to the manufacturer's instructions for use

    Other: Suprathel®

  • Active comparator
    Standard of Care

    The Standard of care as prescribed will be followed for the dressing application for the wound site. Dressings will be applied to the wound site after standard of care cleaning and debridement.

    Other: Suprathel®

Interventions

  • OtherSuprathel®

    Application of standard of care dressing.®

    Also known as: standard of care

06

What researchers measure

Primary outcomes

  1. Need for autograft application

    The reduction of need for grafting measured by the percentage of subjects who are converting to grafting at 21 ± 3 days after application.

    Time frame: 21 days

Secondary outcomes

  1. Wound infection rate, wound closure of the region

    Incidence of infections and inflammatory response and scar development

    Time frame: 2 weeks, 3 weeks, and 6 weeks after application (without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart)

  2. Mid and long term clinical scar maturation assessed by the Patient and Observer Scar Assessment Scale (POSAS).

    Patient and Observer Scar Assessment Scale (POSAS) Questionnaire is used to assess scarring.

    Time frame: Mid (3-9 months) and long term (52 weeks)

  3. Patient-reported perception of pain based on the Visual Analog Scale

    Patients will be asked to rate their pain 0-10 (0=no pain and 10=a lot of pain) prior to and after application of the first dressing and subsequent dressings.

    Time frame: After initial application (Day 0) and weekly

07

Study locations

1 site
  • North Carolina Jaycee Burn Center
    Chapel Hill, North Carolina 27599, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 211 non-industry interventional studies with no phase under Burns, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 26 months is above that.

Counting every sponsor, half of 240 studies reached it within 15 months; a quarter within 6 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2022
First posted
Jul 18, 2022
StartActual
Sep 18, 2024
Primary completionEst.
Dec 9, 2026
CompletionEst.
Dec 9, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05462860
Lead sponsor
The Metis Foundation
Responsible party
Sponsor
First posted
Jul 18, 2022
Start date
Sep 18, 2024
Primary completion
Dec 9, 2026 (estimated)
Completion
Dec 9, 2026 (estimated)
Last update
Aug 13, 2026

Study contacts

Rodney Chan, MD
principal investigator · Metis Foundation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion